NASDAQ:AVGR - Avinger Stock Price, Forecast & News

Avinger trades on the NASDAQ under the ticker symbol "AVGR."

Avinger shares reverse split on Wednesday, January 31st 2018. The 1-40 reverse split was announced on Tuesday, January 30th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 30th 2018. An investor that had 100 shares of Avinger stock prior to the reverse split would have 3 shares after the split.

Avinger Inc (NASDAQ:AVGR) issued its quarterly earnings data on Tuesday, November, 5th. The medical device company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.10. The medical device company earned $2.41 million during the quarter. Avinger had a negative net margin of 237.51% and a negative return on equity of 197.22%. View Avinger's Earnings History.

Avinger is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Avinger.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avinger.

News articles about AVGR stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avinger earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned news headlines about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Avinger.

Some companies that are related to Avinger include SANUWAVE Health (SNWV), Arch Therapeutics (ARTH), Endologix (ELGX), Invo Bioscience (IVOB), Interpace Diagnostics Group (IDXG), Neovasc (NVCN), RA Medical Systems (RMED), Co-Diagnostics (CODX), DarioHealth (DRIO), Biostage (BSTG), Titan Medical (TMDI), Obalon Therapeutics (OBLN), Atossa Genetics (ATOS), Hancock Jaffe Laboratories (HJLI) and PlusTherapeuticsInc . (PSTV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include AcelRx Pharmaceuticals (ACRX), Palatin Technologies (PTN), Alibaba Group (BABA), Aralez Pharmaceuticals (ARLZ), AVEO Pharmaceuticals (AVEO), Biocept (BIOC), Bellerophon Therapeutics (BLPH), Micron Technology (MU), SCYNEXIS (SCYX) and Trevena (TRVN).

(AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company acted as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

Shares of AVGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVGR stock can currently be purchased for approximately $1.14.

Avinger has a market capitalization of $11.81 million and generates $7.91 million in revenue each year. The medical device company earns $-27,560,000.00 in net income (profit) each year or ($33.40) on an earnings per share basis. View Additional Information About Avinger.

The official website for Avinger is http://www.avinger.com/.

Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The medical device company can be reached via phone at 650-241-7900 or via email at [email protected]